Nasdaq · Healthcare

IDEAYA Biosciences, Inc. (IDYA)

As-reported financials and recent SEC filings for IDEAYA Biosciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$218.7M

Net income

$-113.7M

Net margin

-52.0%

Diluted EPS

$-1.28

ROE

-11.1%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$218.7M	$7.0M	$23.4M	$50.9M	$27.9M
Gross profit	—	—	—	—	—
Operating income	$-159.3M	$-327.0M	$-134.4M	$-62.5M	$-50.3M
Net income	$-113.7M	$-274.5M	$-113.0M	$-58.7M	$-49.8M
Diluted EPS	$-1.28	$-3.36	$-1.96	$-1.42	$-1.41

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-23

42026-06-18

42026-06-18

42026-06-18

42026-06-18

42026-06-18

42026-06-18

8-K2026-06-10

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on IDYA

Search IDEAYA Biosciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.